Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207,440,936
-
Total 13F shares
-
98,221,986
-
Share change
-
-14,749,545
-
Total reported value
-
$96,659,560
-
Put/Call ratio
-
432%
-
Price per share
-
$0.98
-
Number of holders
-
161
-
Value change
-
-$21,194,525
-
Number of buys
-
72
-
Number of sells
-
73
Institutional Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q2 2025
As of 30 Jun 2025,
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) was held by
161 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
98,221,986 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, WASATCH ADVISORS LP, Two Seas Capital LP, PenderFund Capital Management Ltd., MARSHALL WACE, LLP, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, Indaba Capital Management, L.P., and CITADEL ADVISORS LLC.
This page lists
161
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.